US equities |
NVDA $239.71 ▲+2.46% SPCX $169.67 ▲+6.74% MU $1,061.36 ▼-1.26% TSLA $380.50 ▲+2.67% SNDK $1,694.71 ▼-1.47% MSFT $528.81 ▲+2.18% INTC $116.47 ▼-2.40% META $743.71 ▲+2.15%
FinancialContent

Voyager Acquisition Corp - Class A Ordinary Shares (NQ:VACH)

17.11 UNCHANGED
Last Price Updated: 3:58 PM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Voyager Acquisition Corp - Class A Ordinary Shares

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Completes Business Combination and Begins Trading on Nasdaq
Via Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’
Via Investor Brand Network
Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG
From Voyager Acquisition Corp.
Via GlobeNewswire
News headline image
Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG
From Voyager Acquisition Corp.
Via GlobeNewswire
News headline image
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
From Voyager Acquisition Corp.
Via GlobeNewswire
News headline image
BioMedNewsBreaks — VERAXA Biotech AG and Voyager Acquisition Corp. (NASDAQ: VACH, “Voyager”) Announce $1.64 Billion Business Combination to Create Clinical-Stage Cancer Therapy Powerhouse
Via Investor Brand Network
News headline image
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer
Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies 
From VERAXA Biotech AG
Via GlobeNewswire